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Abstract
BACKGROUND: Over the past ten years, Rapid Diagnostic Tests (RDT) played
a major role in improving the use of biological malaria diagnosis, in particular
in poor-resources settings. In Burkina Faso, a recent Demography and Health
Survey (DHS) gave the opportunity to assess the performance of the Paracheck®
test in under five children nationwide at community level. METHODS: A national
representative sample of 14,947 households was selected using a stratified two-
stage cluster sampling. In one out of two households, all under five children
were eligible to be tested for malaria using both RDT and microscopy diagnosis.
Paracheck® performance was assessed using miscroscopy as the gold standard.
Sensitivity and specificity were calculated as well as the diagnosis accuracy
(DA) and the Youden index. RESULTS: The malaria infection prevalence was
estimated at 66% (95% CI: 64.8-67.2) according to microscopy and at 76.2%
(95% CI: 75.1-77.3) according to Paracheck®. The sensitivity and speci...
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Introduction
Over the last 50 years, clinical research and 
development of new treatments have been instrumental 
in transforming the care of patients with haemophilia. 
Life expectancy for people with severe haemophilia 
has increased from 16-23 years in the first-half of the 
20th century to more than 65 years nowadays, and 
many such people are now able to lead active and 
fulfilled lives1,2. All this has been possible largely 
through the commitment of people with haemophilia to 
participate actively in clinical research. Despite major 
achievements, there are still several issues to resolve, 
such as the development of longer-acting clotting factor 
concentrates, new bypassing agents, gene therapy, as well 
as new treatment strategies for preventing or reducing 
the risk of developing inhibitors2,3. Although numerous 
clinical trials are ongoing worldwide right now, most 
investigators face difficulties in recruiting appropriate 
candidates, particularly in developed countries4-7.
There is thus a major unmet need for improved patient 
awareness regarding the relevance of clinical haemophilia 
research and promotion of opportunities to participate 
actively in clinical trials4-7. A survey was launched to 
evaluate the motivation of people with haemophilia to 
enter clinical trials in a developed country (Belgium) 
in which they have unlimited and unrestricted access 
to efficient treatments, and to identify factors that may 
influence their willingness to participate. 
Materials and methods
Participants
A specific questionnaire was sent to 135 adults 
with haemophilia regularly attending the Haemophilia 
Comprehensive Centre of the Saint-Luc University 
Hospital in Brussels, Belgium, between June 2011 
and December 2012. The questionnaire was first 
sent by post, with an email reminder sent using 
the online version. Overall, 62 patients completed 
Background. Over the last 50 years, clinical research investigating new treatments has been 
transforming the care of patients with haemophilia but we still have a long way to go and most clinical 
investigators are facing difficulties in recruiting appropriate candidates. A survey was conducted to 
evaluate what motivates people with haemophilia to participate in clinical research and to identify 
factors that might influence their willingness to participate. 
Material and methods. A specific questionnaire concerning motivation and barriers to 
participation in clinical trials was sent to 135 adults with haemophilia. A classification tree was used 
to identify predictors of willingness to participate. 
Results. Sixty-two patients returned the completed questionnaire, of whom 51 declared a potential 
willingness to participate in a clinical trial, although many were concerned about the new treatments' 
possible side effects or about time away from work. Predictors of willingness to participate were 
evaluated using a classification tree and four groups were established. Group 1 comprised patients 
aged ≤45 years old. Group 2 comprised patients >45 years old who reported having no knowledge of 
clinical research modalities. The two other groups comprised patients >45 years old who reported having 
some knowledge of clinical research modalities, with group 3 being ≤59 years old and group 4 being 
>59 years old. The rate of willingness to participate was 96.6%, 28.6%, 70.6% and 100.0%, 
respectively. 
Discussion. The rate of willingness to participate in clinical research was significantly lower in 
patients who reported having no knowledge of clinical trial modalities, highlighting the relevance 
of providing improved knowledge about the modalities, risks, and benefits of clinical research to 
enhance participation in haemophilia trials. 
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Patients’ motivation for participating in haemophilia research
the questionnaire (n=62/135, 45.9%). All the 
people who did not complete the questionnaire 
were contacted by phone in order to determine the 
reasons why they did not return the questionnaire.
Study measures
The questionnaire addressed socio-demographic 
status, family context, current haemophilia treatment, 
knowledge of principles and of perceived benefits 
and risks of clinical research, as well as positive and 
negative factors influencing motivation to participate. 
Socio-demographic data including age, country of residence, 
time spent in Belgium, country of origin, educational 
background, and primary occupation, were also collected.
Family data covered family context, number of children, 
number of affected males in the family and entourage, 
carriers in the family and entourage, as well as haemophilia 
mortality instances in males of the family and entourage.
Haemophilia treatment and care data included 
haemophilia type (A or B) and severity (severe, moderate, 
or mild), medication (recombinant or plasma-derived 
factor VIII or factor IX, or desmopressin), treatment 
regimen (prophylaxis or on-demand), total number of 
years on prophylaxis, current clotting factor concentrate 
consumption, inhibitor development in the past, estimated 
number of hospital admissions because of haemophilia, 
use of a notebook to record injections, and distance from 
the haemophilia centre.
Clinical research data included knowledge about clinical 
trials, the different phases of new drug development prior 
to marketing, number of participants needed, relevance of 
participation in clinical trials, awareness of clinical research, 
prior participation in a clinical trial, general interest in 
clinical trials, willingness to participate in a clinical trial, 
and which study phase they would agree to participate in, 
as well as perceived risks and benefits of participating in a 
clinical trial. A clinical trial was defined as a study aiming 
to develop or validate new treatments for haemophilia.
The study was approved by the local Ethical Committee, 
and informed written consent was obtained from all 
participants.
Statistical analysis
Continuous variables were expressed as means 
and standard deviations when they were normally 
distributed and as medians (p25 and p75) when they 
were not normally distributed. Continuous variables 
were compared using an independent Student's t-test, 
Mann-Whitney U test, or the Kruskal-Wallis test 
depending on the validity conditions of each test. 
Categorical variables were compared using the Pearson's 
chi-squared test or Fisher's exact test, as appropriate. 
A classification tree analysis was used to analyse 
predictors of willingness to participate in clinical trials. 
The classification tree-based models were non-linear 
and non-parametric alternatives to linear models for 
classification problems8. Classification tree models were 
fitted by recursive partitioning of a multidimensional 
covariate space, in which the dataset was successively 
split into homogeneous subgroups. The selected split 
was the one that maximised the homogeneity of the two 
resulting nodes with respect to the response variable. 
The minimum-cost tree was selected as the best tree and 
the Gini index was used to measure the homogeneity of 
each node. A random forest was used as an additional 
tool to provide a variable ranking based on the overall 
contribution to the tree construction. Statistical analyses 
were performed using R software version 2.15.1 
(Free Software Foundation, Inc., Boston, MA, USA) and 
Salford Predictive Modeler Builder Version 6.6 (Salford 
Systems, San Diego, CA, USA). A p value <0.05 was 
considered statistically significant. 
Results
A total of 135 questionnaires were sent to adults 
with haemophilia (≥18 years), and 62 completed 
questionnaires were returned (n=62/135, 45.9%).
Reasons for not completing the questionnaire
Among the 73 patients who did not complete the 
questionnaire, ten patients did not remember having 
received it, one patient had died, three patients had moved 
and had not received the questionnaire, three patients 
thought they had returned it, four patients declared that 
it was an oversight not having completed it, one patient 
stated that he did not have the time to complete it, and 
45 patients did not respond, despite several attempts. Four 
patients thought their participation was not necessary 
because they have mild or moderate haemophilia treated 
by on-demand therapy with minor impact on their life 
and two patients declared they did not want to complete 
the questionnaire, including one who do not accept his 
haemophilia status.
Patients who completed the questionnaire
The age of patients who completed the questionnaire 
was higher than that of those who did not (median age: 48.0 
vs 42.0 years, p=0.045) (Table I). The proportion of patients 
on prophylaxis was not significantly different between 
patients who completed the questionnaire and those who 
did not (46.8% [n=29/62] vs 30.6% [n=22/73]; p=0.054). 
The distribution of types of haemophilia was similar in the 
two groups (p=0.300), with a total of 80.0% of individuals 
having haemophilia A and 20.0% having haemophilia B. 
Among the 62 patients who responded, 11 (17.7%) 
declared they would refuse to participate in a clinical 
trial (Table II). The 11 patients who did not want to 
participate in a clinical trial were older than those who 
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were willing to participate, with a mean age of 57.6 years 
vs 45.3 years, respectively (p=0.017). The proportion 
of people willing to participate in a clinical trial did not 
differ significantly between educational levels, although a 
significant trend was observed (chi-squared test for trend; 
p=0.048). Among people who did not graduate from high 
school, 40% (n=4/10) indicated that they were not willing 
to participate in a clinical trial, against 9.5% (n=2/21) of 
the people who have a college degree (Table II).
Impact of family variables
The fact that patients were acquainted with other 
people with haemophilia (54.1%), had one or several 
haemophilia carriers in the family or entourage (72.1%), 
or had had at least one haemophilic male death in the 
family or entourage (34.4%) had no impact on the 
patients' willingness to participate in a clinical trial.
Impact of treatment modalities 
Approximately half of the patients were on 
prophylaxis (46.8%), among whom 44.8% were given 
prophylaxis three times a week, 44.8% twice a week, 
and 10.4% once a week (Table I). Only one of the ten 
patients with haemophilia B was on prophylaxis (10.0%) 
whereas 28 of the 52 patients with haemophilia A were 
on prophylaxis (53.8%). Three patients (4.8%) had 
been on secondary prophylaxis for under a year. Seven 
patients reported having developed an inhibitor in the 
past (11.9%); in six of them this occurred between the 
ages of 5 and 20 years, and in the remaining one at the 
age of 70. Nine patients (14.5%) did not know whether 
they had ever developed an inhibitor in the past. Thirteen 
patients (21.7%, n=13/60; two missing values) reported 
that they had never been admitted to hospital on account 
of haemophilia; these 13 individuals included four 
who had severe haemophilia. The majority of patients 
(58.3%, n=35/60, two missing values) reported between 
one and ten hospital admissions related to haemophilia, 
and 20.0% reported more than ten hospital admissions 
linked to haemophilia.
Knowledge and awareness of clinical trials
Approximately 70% of the patients (n=43/62) 
reported having some knowledge of clinical research 
principles, but only 30.2% of them fully understood the 
different phases of a clinical trial (Table III). Among the 
43 patients who declared knowing what a clinical trial 
is, two-thirds (n=27/43) stated that they have received 
their information from a medical doctor, 14.0% (n=6/43) 
from people around them working in the medical field 
or from the media and 23.3% (n=10/43) from none 
of the above sources. However, patients' knowledge 
about clinical trials appeared to be very limited, as 
the majority reported being unaware of the different 
phases of such trials or of the number of participants 
required for the clinical development of a new drug. 
Twenty-four patients (40.0%; two missing values) had 
already participated in a clinical trial; among these, 
87.5% (n=21) were satisfied and 12.5% were not. In 
addition, 30.5% of patients (n=18/59) knew someone 
who had participated in a clinical trial; of these 
acquaintances, 13 would participate again, two would 
not, and the remaining three were unsure.
With respect to level of knowledge about clinical 
trials, 48.3% felt they were not sufficiently informed, 
with 96.4% wanting more information on trials. 
Conversely, 51.7% felt they were sufficiently informed, 
although 70.0% wanted more information.
The majority of patients considered their involvement 
in clinical trials as relevant (87.7%) (Table III). 
Table I - Characteristics of the 135 patients who were contacted to complete the questionnaire.
Variables
Total (N=135) 
n (%) or 
median [p25; p75]
Non-respondent (n=73) 
n (%) or 
median [p25; p75]
Respondent (n=62) 




Haemophilia A 108 (80.0) 56 (76.7) 52 (83.9)
Haemophilia B 27 (20.0) 17 (23.3) 10 (16.1)
Haemophilia severity 0.230
Severe 69 (51.1) 34 (46.6) 35 (56.5)
Moderate 21 (15.6) 10 (13.7) 11 (17.7)
Mild 45 (33.3) 29 (39.7) 16 (25.8)
Treatment regimen*
On-demand 83 (61.9) 50 (69.4) 33 (53.2) 0.054
Prophylaxis 51 (38.1) 22 (30.6) 29 (46.8)
Age, years 44.0 [31.0; 57.5] 42.0 [27.0; 56.0] 48.0 [36.0; 59.0] 0.045
*1 missing value (0.7%); p: p value for the comparison of patients' characteristics between non-respondents and respondents to the questionnaire.
All rights reserved - For personal use only 









Blood Transfus 2015; 13: 302-9  DOI 10.2450/2014.0152-14
Patients’ motivation for participating in haemophilia research
Table II - Characteristics of the 62 patients who returned the questionnaire.
Total respondents 
to the questionnaire [N=62]
Willing to participate 
in a clinical trial [n=51]
Not willing to participate 
in a clinical trial [n=11] p
n (%) or mean±SD n (%) or mean±SD n (%) or mean±SD
Type of haemophilia 0.674
Haemophilia A 52 (83.9) 42 (82.4) 10 (90.9)
Haemophilia B 10 (16.1) 9 (17.6) 1 (9.1)
Haemophilia severity 0.733
Severe 35 (56.5) 30 (58.8) 5 (45.4)
Moderate 11 (17.7) 9 (17.7) 2 (18.2)
Mild 16 (25.8) 12 (23.5) 4 (36.4)
Treatment regimen 0.569
Prophylaxis 29 (46.8) 23 (45.1) 6 (54.5)
On-demand 33 (53.2) 28 (54.9) 5 (45.5)
Age, years 47.5±14.6 45.3±14.0 57.6±13.9 0.017
Educational level* 0.239
Did not graduate from high school 10 (16.4) 6 (12.0) 4 (36.4)
High school graduate 15 (24.6) 12 (24.0) 3 (27.3)
Some college or 3-year degree 15 (24.6) 13 (26.0) 2 (18.2)
College graduate 21 (34.4) 19 (38.0) 2 (18.2)
Family context* 0.404
Single 14 (23.0) 12 (23.5) 2 (18.2)
Couple 45 (73.7) 37 (72.5) 8 (72.7)
Widower 2 (3.3) 1 (2.0) 1 (9.1)
Having daughters** 0.739
No 30 (50.0) 24 (49.0) 6 (54.5)
Yes 30 (50.0) 25 (51.0) 5 (45.5)
Having sons** 0.317
No 30 (50.0) 26 (53.1) 4 (36.4)
Yes 30 (50.0) 23 (46.9) 7 (63.6)
Notebook for injections**
No 21 (35.0) 18 (36.7) 3 (27.3) 0.731
Yes 39 (65.0) 31 (63.3) 8 (72.7)
* 1 missing value (1.6%);** 2 missing values (3.2%); p: p value for the comparison of patients' characteristics between patients who declared a certain 
willingness to participate in a clinical trial and patients who were not willing to do so; SD: standard deviation.
The reasons why patients considered their involvement 
in clinical trials as unimportant were: limited severity 
of haemophilia (on-demand treatment, n=2/7); old 
age (n=1/7); lack of experience with clinical trials 
(n=1/7); concomitant hepatitis C and perceived risk of 
inhibitor development (n=1/7). Two patients provided no 
explanations.
Perception of the need for new drug development 
Thirty-seven patients (n=37/52, 71.2%, 10 missing 
values) indicated that the development of new haemophilia 
drugs was necessary, 19.2% were neutral, and 9.6% did not 
consider this a necessity. However, 87.0% of patients stated 
that the development of new treatments was desirable. 
The expected improvements quoted were better and 
safer treatments (less risk of infection), reduction in 
the number of weekly injections, availability of more 
effective drugs to control bleeding, development of 
gene therapy, as well as subcutaneous administration. 
Patients expressed a desire for oral tablets (n=3), better 
conservation conditions for transport abroad (n=2), 
and a cure for haemophilia (n=1). Before deciding to 
participate, the majority of patients would discuss the 
decision with their doctor (59.7%), their wife (53.2%), 
their parents (12.9%), or other patients (8.1%), while 
20.0% would make the decision alone. 
Although 29.0% of patients reported that participating 
in a clinical trial would be a source of anxiety or 
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incompatible with their personal/professional life, and 
25.8% reported that it would be an additional constraint 
for them, the majority (59.7%) considered it to be 
an opportunity. One of the major reasons for fearing 
participation was a new drug's potential side-effects 
(Table IV). Other reasons for potential non-participation 
were also stated, such as the purpose and type of study 
(n=3), doctor's approval (n=2), allergies to prior treatments 
(n=1), the perception that the disease was not sufficiently 
severe in one patient with mild haemophilia A (n=1), 
the concern that the tested drug should be developed by 
the same company manufacturing the patient's current 
treatment (n=1), or multiple stays abroad incompatible 
with study participation (n=1). Two patients reported 
having no fears.
Among the 51 patients who were interested in 
participating in a clinical trial, 11 (22.4%, two missing 
values) would accept being the first people with 
haemophilia to receive a new drug, 20 (40.8%) would 
agree to participate in a clinical trial provided the new drug 
had already been tested in other patients and volunteers, 
and 18 (36.7%) would accept taking a new drug if it 
was already on the market in order to help to confirm 
the drug's efficacy and safety. The patients displayed 
some flexibility as regards participating in a clinical trial 
(Table IV). Patients indicated that visits to a hospital could 
pose a problem, mainly because of professional concerns 
(49.0%), long waiting times at the hospital (29.4%) and 
transport issues (23.5%). An interesting result was that 
only 11.8% (n=6/51) of the patients who were interested 
in participating in a clinical trial would do so if they got 
financial compensation.
Predictors of willingness to participate in clinical 
trials
A major finding was that the treatment regimen 
(prophylaxis vs on-demand) had no impact on 
willingness to participate (Table II), nor did the type 
or severity of haemophilia. Predictors of willingness 
to participate in a clinical trial were evaluated 
using a classification tree, which established four 
groups (Figure 1). Group 1 comprised patients aged 
≤45 years: their rate of willingness to participate 
(with 95% confidence interval [95% CI]) was 
96.6% (82.8-99.4%), (n=28/29). Group 2 comprised 
patients aged >45 years old who reported no 
knowledge of clinical research modalities (rate of 
willingness to participate: 28.6% [95% CI: 5.1-69.7%]; 
n=2/7). Group 3 comprised patients aged between 
46 and 59 years old who reported some knowledge 
of clinical research modalities (rate of willingness to 
participate: 70.6% [95% CI: 46.9-86.7%]; n=12/17). 





I do not know
n (%)
Do you know what a clinical trial is? 43 (69.4) 7 (11.3) 12 (19.4)
Do you know the different phases of a clinical trial?* 13 (21.3) 34 (55.7) 14 (23.0)
In your opinion, should each factor VIII or IX concentrate be evaluated in a clinical trial 
prior to marketing authorisation?*
43 (70.5) 3 (4.9) 15 (24.6)
Do you have an idea of the number of participants required to develop new clotting factor 
concentrates for haemophilia treatment?*
7 (11.5) 47 (77.0) 7 (11.5)
Could you estimate the number of participants needed to develop new clotting factor 
concentrates?*
12 (19.7) 44 (72.1) 5 (8.2)
Do you consider your involvement in clinical trials important?** 50 (87.7) 7 (12.3) /
* 1 missing value (1.6%);** 5 missing values (8.1%)
Table IV - Reasons that could be an obstacle to an active 
participation in a clinical trial in the 51 patients 
who would have been willing to participate in 
such a trial.
n (%)
Reasons for non-participation in clinical trials
Clinical trials imply too many visits to the hospital 23 (45.1)
I care about the risks (side-effects) of a new drug. I do not 
want to take these risks
20 (39.2)
I do not want to change my coagulation factor concentrate 4 (7.8)
I do not want to change my actual treatment scheme. I do 
not want to have more frequent infusions
3 (5.9)
Questions assessing flexibility and tolerance of patients agreeing to 
take part in a clinical trial
Spending a day at the hospital for a kinetic study 31 (60.8)
Spending a night at the hospital 28 (54.9)
Filling out a notebook regarding infusions several times 
a week
28 (54.9)
Going to the hospital once a month for the trial 25 (49.0)
Receiving a placebo and a real drug 17 (31.5)
Change of treatment scheme (more frequent infusions) 13 (25.5)
None of these propositions 2 (3.9)
All rights reserved - For personal use only 









Blood Transfus 2015; 13: 302-9  DOI 10.2450/2014.0152-14
Patients’ motivation for participating in haemophilia research
Finally, group 4 comprised patients aged >59 years 
who reported some knowledge of clinical research 
modalities (rate of willingness to participate: 100.0% 
[95% CI: 62.9-100.0%]; n=9/9). The proportions of 
patients who were willing to take part in a clinical trial 
differed significantly between group 1 and groups 2 
and 3 and between group 2 and group 4. Table V shows 
other variables that were important in the construction 
of the classification tree. Other variables had no impact 
on willingness to participate (importance of 0.0).
Discussion
Various studies reported in the scientific literature 
mention the importance of developing further research 
and new drugs in the field of haemophilia. Since the 
participation of patients in clinical research is essential 
for the advance of science, and the recruitment of a 
sufficient number of participants in clinical trials is 
crucial for health care to progress, we need to increase 
the number of patients willing to participate in clinical 
trials by enhancing their motivation2-7. 
To the best of our knowledge, this is the first study 
that has evaluated the factors influencing the willingness 
of people with haemophilia to participate in clinical 
research. The authors are not aware of any studies 
that have assessed the knowledge that adults with 
haemophilia have about clinical trials or motivation 
for participating in such trials, rendering it difficult to 
compare the findings of the present study with literature 
data. Given that haemophilia is a rare and chronic disease, 
now well-tolerated because of new treatments that are 
available in developed countries, such as Belgium, it 
is difficult to compare the willingness of people with 
haemophilia to participate in clinical research with that 
of patients suffering from other diseases, such as cancer 
or diabetes. In contrast to other prevalent diseases, the 
Figure 1 - Classification tree representing the important predictors of willingness to participate in clinical trials (n=62). 
 The selected splitting variables (patients' reported knowledge of clinical trials and age) are shown in the nodes. Motivation: 
rate of willingness to participate in clinical trials; non-motivation: rate of non-willingness to participate in clinical trials.
Table V -  Ranking of variables for willingness to participate 




Patient's interest in having more information about clinical trials 36.0
Patient's knowledge about clinical trials 26.3
Profession 14.1
Severity of haemophilia 12.7
Type of haemophilia 10.3
Family context 4.4
Patient's awareness of clinical trials 0.2
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relatively low number of potential participants is a 
relevant barrier for a rare disease such as haemophilia. 
However, several studies, essentially evaluating 
patients' willingness to participate in clinical trials, as 
well as barriers to the patients' participation, have been 
carried out in other medical fields, such as oncology9,10. 
In line with our study, these studies found that fear of a 
new drug's potential side-effects, additional procedures 
and appointments needed for clinical trials, as well as 
travel problems and related costs were potential barriers 
to active participation in the trials9,10.
The main finding of our study was that patients 
who were >45 years old and who declared having no 
knowledge about clinical trials were less motivated to 
participate (rate of willingness to participate: 28.6%; 
n=2/7). These findings support the view that physicians 
should provide patients with clear and unbiased 
information on clinical research, such as information 
leaflets explaining clinical trials. A website was 
developed at the Haemophilia Comprehensive Centre of 
the Saint-Luc University Hospital in Brussels, Belgium, 
in order to increase patients' awareness of the importance 
of participating in clinical research on haemophilia 
(http://participatetoinnovate.com), explaining the different 
clinical research steps, why patients' participation 
is required, what challenges remain in the field of 
haemophilia therapy, and the expected benefits of 
participating in a study. A leaflet was also made available 
to patients, inviting them to consult the website. Our 
study also suggested that willingness to participate is 
affected by educational level, given the significant trend 
of willingness to participate in a clinical trial observed 
with increasing educational level.
Three major biases of our study must be noted. First, 
there may have been a bias due to the participation 
rate, with less that half of the patients returning the 
questionnaire (46.7%; n=62/135). Among the 73 patients 
who did not complete the questionnaire, one patient had 
died, three patients had moved and did not receive the 
questionnaire, ten patients did not remember having 
received the questionnaire, three patients thought they 
had returned it and 45 patients did not respond, despite 
several attempts. Secondly, there may have been a 
bias related to the fact that patients who completed the 
questionnaire were older than those who did not. Only 
11.3% of patients who completed the questionnaire 
were aged ≤30 years compared to 32.9% for the others; 
suggesting that younger patients were less interested 
in their disease, possibly because they benefitted 
from current well-tolerated and effective haemophilia 
therapies, whereas older patients were likely infected 
following blood transfusions in the 1980s. Another 
reason could be that not all patients aged ≤30 years have 
children, so the question of haemophilia transmission to 
their daughters is not of immediate interest. The third 
potential bias was related to the higher proportion of 
patients being treated on-demand among those who did 
not return the questionnaire (69.4% for non-respondents 
vs 53.2% for respondents) even if these proportions 
were not statistically significantly different (p=0.054). 
Patients receiving on-demand therapy probably felt 
less concerned about their haemophilia, as indicated 
by the four patients with mild or moderate haemophilia 
treated by on-demand therapy who did not complete the 
questionnaire because haemophilia has a minor impact 
on their life. Moreover, patients on prophylaxis are 
more likely to have regular contact with the treatment 
centre, probably resulting in the higher proportion of 
respondents to the questionnaire among these patients. 
Given the significant non-response rate, the reported 
findings may represent the basis for further larger studies. 
As an example, non-respondents could be asked to fill 
out the questionnaire at a routine clinical follow-up at 
the haemophilia centre. We also encourage this approach 
for other questionnaire-based studies in order to increase 
participation rate. Moreover, multicentre collaborative 
studies could be conducted in the near future. In 
addition, this study should be repeated on a larger 
scale in order to confirm our findings and to underline 
potential differences between countries and between 
patients with various levels of access to treatment, 
such as a prophylaxis scheme. Results from patients 
in our developed country who have access to optimal 
treatment could differ from those in other countries, 
both developed and developing, in which patients do not 
have access to optimal treatment or have no access at all.
Conclusion
In conclusion, this survey highlights the relevance of 
increasing awareness and providing improved knowledge 
of clinical research modalities, risks, and benefits in 
order to increase the number of potential participants 
in clinical haemophilia trials. The conclusion of this 
study cannot, however, be extrapolated to all people 
with haemophilia, because of different access rates to 
prophylaxis depending on the country. We recommend 
that similar surveys be conducted in other developed 
and developing countries.
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